OBJECTIVE: To compare the risk of incident hyperlipidemia in early rheumatoid arthritis (RA) patients after initiation of various disease-modifying antirheumatic drugs (DMARDs). METHODS: We conducted a cohort study using insurance claims data (2001-2012) in early RA patients. Early RA was defined by the absence of any RA diagnosis or DMARD prescriptions for 12 months. Four mutually exclusive groups were defined based on DMARD initiation: tumor necrosis factor α (TNFα) inhibitors ± nonbiologic (nb) DMARDs, methotrexate (MTX) ± nonhydroxycholorquine nbDMARDs, hydroxychloroquine ± non-MTX nbDMARDs, and other nbDMARDs only. The primary outcome was incident hyperlipidemia, defined by a diagnosis and a prescription for a lipid-lowering agent. For the subgroup of patients with laboratory results available, change in lipid levels was assessed. Multivariable Cox proportional hazard models and propensity score (PS) decile stratification with asymmetric trimming were used to control for confounding. RESULTS: Of the 17,145 early RA patients included in the study, 364 developed incident hyperlipidemia. The adjusted hazard ratios (HRs; 95% confidence intervals [95% CIs]) for hyperlipidemia were 1.41 (95% CI 0.99, 2.00) for TNFα inhibitors, 0.81 (95% CI 0.63, 1.04) for hydroxychloroquine, and 1.33 (95% CI 0.95, 1.84) for other nbDMARDs compared with MTX in the full cohort, while HRs for the PS trimmed cohort were 1.18 (95% CI 0.80, 1.73), 0.75 (95% CI 0.58, 0.98), and 1.41 (95% CI 1.01, 1.98), respectively. In the subgroup analysis, hydroxychloroquine use showed significant reduction in low-density lipoprotein (-8.9 mg/dl, 95% CI -15.8, -2.0), total cholesterol (-12.3 mg/dl, 95% CI -19.8, -4.8) and triglyceride levels (-19.5 mg/dl, 95% CI -38.7, -0.3) from baseline compared with MTX. CONCLUSION: Use of hydroxychloroquine may be associated with a lower risk of hyperlipidemia among early RA patients.
OBJECTIVE: To compare the risk of incident hyperlipidemia in early rheumatoid arthritis (RA) patients after initiation of various disease-modifying antirheumatic drugs (DMARDs). METHODS: We conducted a cohort study using insurance claims data (2001-2012) in early RApatients. Early RA was defined by the absence of any RA diagnosis or DMARD prescriptions for 12 months. Four mutually exclusive groups were defined based on DMARD initiation: tumor necrosis factor α (TNFα) inhibitors ± nonbiologic (nb) DMARDs, methotrexate (MTX) ± nonhydroxycholorquine nbDMARDs, hydroxychloroquine ± non-MTX nbDMARDs, and other nbDMARDs only. The primary outcome was incident hyperlipidemia, defined by a diagnosis and a prescription for a lipid-lowering agent. For the subgroup of patients with laboratory results available, change in lipid levels was assessed. Multivariable Cox proportional hazard models and propensity score (PS) decile stratification with asymmetric trimming were used to control for confounding. RESULTS: Of the 17,145 early RApatients included in the study, 364 developed incident hyperlipidemia. The adjusted hazard ratios (HRs; 95% confidence intervals [95% CIs]) for hyperlipidemia were 1.41 (95% CI 0.99, 2.00) for TNFα inhibitors, 0.81 (95% CI 0.63, 1.04) for hydroxychloroquine, and 1.33 (95% CI 0.95, 1.84) for other nbDMARDs compared with MTX in the full cohort, while HRs for the PS trimmed cohort were 1.18 (95% CI 0.80, 1.73), 0.75 (95% CI 0.58, 0.98), and 1.41 (95% CI 1.01, 1.98), respectively. In the subgroup analysis, hydroxychloroquine use showed significant reduction in low-density lipoprotein (-8.9 mg/dl, 95% CI -15.8, -2.0), total cholesterol (-12.3 mg/dl, 95% CI -19.8, -4.8) and triglyceride levels (-19.5 mg/dl, 95% CI -38.7, -0.3) from baseline compared with MTX. CONCLUSION: Use of hydroxychloroquine may be associated with a lower risk of hyperlipidemia among early RApatients.
Authors: Elisabetta Patorno; Rhonda L Bohn; Peter M Wahl; Jerry Avorn; Amanda R Patrick; Jun Liu; Sebastian Schneeweiss Journal: JAMA Date: 2010-04-14 Impact factor: 56.272
Authors: Alper M van Sijl; Mike J L Peters; Dirk L Knol; Riekie H C de Vet; Naveed Sattar; Ben A C Dijkmans; Yvo M Smulders; Michael T Nurmohamed Journal: Semin Arthritis Rheum Date: 2011-06-12 Impact factor: 5.532
Authors: Sebastian Schneeweiss; Mike Doherty; Shao Zhu; Donnie Funch; Raymond G Schlienger; Carlos Fernandez-Vidaurre; John D Seeger Journal: Dermatology Date: 2009-03-17 Impact factor: 5.366
Authors: David Hürlimann; Adrian Forster; Georg Noll; Frank Enseleit; Rémy Chenevard; Oliver Distler; Markus Béchir; Lukas E Spieker; Michel Neidhart; Beat A Michel; Renate E Gay; Thomas F Lüscher; Steffen Gay; Frank Ruschitzka Journal: Circulation Date: 2002-10-22 Impact factor: 29.690
Authors: Joyce C Chang; Rui Xiao; Andrea M Knight; Stephen E Kimmel; Laura M Mercer-Rosa; Pamela F Weiss Journal: Semin Arthritis Rheum Date: 2020-05-03 Impact factor: 5.532
Authors: Rishi J Desai; Daniel H Solomon; Sebastian Schneeweiss; Goodarz Danaei; Katherine P Liao; Seoyoung C Kim Journal: Epidemiology Date: 2016-05 Impact factor: 4.822
Authors: Lucia Sobrin; Yinxi Yu; Samuel Han; Gayatri Susarla; John H Kempen; Rebecca A Hubbard; Brian L VanderBeek Journal: Graefes Arch Clin Exp Ophthalmol Date: 2021-05-29 Impact factor: 3.535
Authors: Lucia Sobrin; Yinxi Yu; Samuel Han; Gayatri Susarla; John H Kempen; Rebecca A Hubbard; Brian L VanderBeek Journal: Ocul Immunol Inflamm Date: 2021-03-08 Impact factor: 3.728